Heparin-induced thrombocytopenia (HIT) is an immune-mediated platelet disorder caused by antibodies that target complexes of platelet factor 4 (PF4) and heparin. HIT has been characterized as a ...

Please provide your email address to receive an email when new articles are posted on . “This is a really exciting new mechanism of action for our field, hoping to improve functional as well as ...

However, semaglutide treatment was associated with a significantly increased risk of nonarteritic anterior ischemic optic neuropathy. HealthDay News — For adults with diabetes, semaglutide treatment ...

Semaglutide showed no significant association with increased risk of eye disorders or diabetic retinopathy in the meta-analysis. A potential link between semaglutide and increased risk of NAION was ...

MONDAY, Aug. 18, 2025 (HealthDay News) -- For adults with diabetes, semaglutide treatment is not associated with increased risk of eye disorders or diabetic retinopathy, according to a review ...

Boehringer Ingelheim has inked a deal with Palatin Technologies worth up to €280 million (about $327 million) biobucks with the aim of developing new retinal disease therapies. The German drugmaker ...

Please provide your email address to receive an email when new articles are posted on . Ford Medical will distribute AEYE-DS to U.S. pharmacies and non-acute centers. The system pairs with a retinal ...

New research has discovered certain weight-loss medications could be associated with an increased risk of serious eye conditions, and even vision loss. Two studies, published in JAMA, analyzed how ...

More than a decade ago, researchers found that an acute complication of type 1 diabetes, diabetic ketoacidosis (DKA), can be resolved with the hormone leptin, even in the absence of insulin. DKA ...

More than a decade ago, researchers found that an acute complication of type 1 diabetes, diabetic ketoacidosis (DKA), can be resolved with the hormone leptin, even in the absence of insulin. An ...

EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedema Phase IIb trial to ...

High levels of the protein interleukin 6 (IL-6) in the aqueous fluid of the eye may be a powerful biomarker for evaluating the severity of diabetic eye disease and could help identify patients at the ...